310 related articles for article (PubMed ID: 8691458)
1. Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action.
Fournie-Zaluski MC; Coric P; Thery V; Gonzalez W; Meudal H; Turcaud S; Michel JB; Roques BP
J Med Chem; 1996 Jun; 39(13):2594-608. PubMed ID: 8691458
[TBL] [Abstract][Full Text] [Related]
2. Optimal recognition of neutral endopeptidase and angiotensin-converting enzyme active sites by mercaptoacyldipeptides as a means to design potent dual inhibitors.
Coric P; Turcaud S; Meudal H; Roques BP; Fournie-Zaluski MC
J Med Chem; 1996 Mar; 39(6):1210-9. PubMed ID: 8632427
[TBL] [Abstract][Full Text] [Related]
3. Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
Fink CA; Carlson JE; McTaggart PA; Qiao Y; Webb R; Chatelain R; Jeng AY; Trapani AJ
J Med Chem; 1996 Aug; 39(16):3158-68. PubMed ID: 8759637
[TBL] [Abstract][Full Text] [Related]
4. Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats.
Gonzalez Vera W; Fournié-Zaluski MC; Pham I; Laboulandine I; Roques BP; Michel JB
J Pharmacol Exp Ther; 1995 Jan; 272(1):343-51. PubMed ID: 7815350
[TBL] [Abstract][Full Text] [Related]
5. Antihypertensive and natriuretic effects of CGS 30440, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11.
Chatelain RE; Ghai RD; Trapani AJ; Odorico LM; Dardik BN; De Lombaert S; Lappe RW; Fink CA
J Pharmacol Exp Ther; 1998 Mar; 284(3):974-82. PubMed ID: 9495857
[TBL] [Abstract][Full Text] [Related]
6. New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension.
Fournié-Zaluski MC; Coric P; Turcaud S; Rousselet N; Gonzalez W; Barbe B; Pham I; Jullian N; Michel JB; Roques BP
J Med Chem; 1994 Apr; 37(8):1070-83. PubMed ID: 8164250
[TBL] [Abstract][Full Text] [Related]
7. Marked difference between angiotensin-converting enzyme and neutral endopeptidase inhibition in vivo by a dual inhibitor of both enzymes.
Anastasopoulos F; Leung R; Kladis A; James GM; Briscoe TA; Gorski TP; Campbell DJ
J Pharmacol Exp Ther; 1998 Mar; 284(3):799-805. PubMed ID: 9495836
[TBL] [Abstract][Full Text] [Related]
8. Dual metalloprotease inhibitors. 6. Incorporation of bicyclic and substituted monocyclic azepinones as dipeptide surrogates in angiotensin-converting enzyme/neutral endopeptidase inhibitors.
Robl JA; Cimarusti MP; Simpkins LM; Brown B; Ryono DE; Bird JE; Asaad MM; Schaeffer TR; Trippodo NC
J Med Chem; 1996 Jan; 39(2):494-502. PubMed ID: 8558518
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure.
Trippodo NC; Robl JA; Asaad MM; Bird JE; Panchal BC; Schaeffer TR; Fox M; Giancarli MR; Cheung HS
J Pharmacol Exp Ther; 1995 Nov; 275(2):745-52. PubMed ID: 7473162
[TBL] [Abstract][Full Text] [Related]
10. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension.
Pham I; Gonzalez W; el Amrani AI; Fournié-Zaluski MC; Philippe M; Laboulandine I; Roques BP; Michel JB
J Pharmacol Exp Ther; 1993 Jun; 265(3):1339-47. PubMed ID: 8389863
[TBL] [Abstract][Full Text] [Related]
11. Vasopeptidase inhibitors: incorporation of geminal and spirocyclic substituted azepinones in mercaptoacyl dipeptides.
Robl JA; Sulsky R; Sieber-McMaster E; Ryono DE; Cimarusti MP; Simpkins LM; Karanewsky DS; Chao S; Asaad MM; Seymour AA; Fox M; Smith PL; Trippodo NC
J Med Chem; 1999 Jan; 42(2):305-11. PubMed ID: 9925736
[TBL] [Abstract][Full Text] [Related]
12. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
Campbell DJ; Anastasopoulos F; Duncan AM; James GM; Kladis A; Briscoe TA
J Pharmacol Exp Ther; 1998 Nov; 287(2):567-77. PubMed ID: 9808682
[TBL] [Abstract][Full Text] [Related]
13. Cell surface metallopeptidases involved in blood pressure regulation: structure, inhibition and clinical perspectives.
Roques BP
Pathol Biol (Paris); 1998 Mar; 46(3):191-200. PubMed ID: 9769915
[TBL] [Abstract][Full Text] [Related]
14. Antihypertensive properties of a new long-acting angiotensin converting enzyme inhibitor in renin-dependent and independent hypertensive models.
Nagata S; Takeyama K; Fukuya F; Nagai R; Hosoki K; Nishimura K; Deguchi T; Karasawa T
Arzneimittelforschung; 1995 Aug; 45(8):853-8. PubMed ID: 7575746
[TBL] [Abstract][Full Text] [Related]
15. New alpha-thiol dipeptide dual inhibitors of angiotensin-I converting enzyme and neutral endopeptidase EC 3.4.24.11.
Fink CA; Qiao Y; Berry CJ; Sakane Y; Ghai RD; Trapani AJ
J Med Chem; 1995 Dec; 38(26):5023-30. PubMed ID: 8544178
[TBL] [Abstract][Full Text] [Related]
16. [Dual inhibition of converting enzyme and neutral endopeptidase: a research new way in the field of hypertension].
Fournie-Zaluski MC
C R Seances Soc Biol Fil; 1992; 186(6):612-25. PubMed ID: 1339591
[TBL] [Abstract][Full Text] [Related]
17. Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels.
Duncan AM; James GM; Anastasopoulos F; Kladis A; Briscoe TA; Campbell DJ
J Pharmacol Exp Ther; 1999 Apr; 289(1):295-303. PubMed ID: 10087017
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and enzymatic evaluation of novel partially fluorinated thiol dual ACE/NEP inhibitors.
Olimpieri F; Tambaro S; Fustero S; Lazzari P; Sanchez-Roselló M; Pani L; Volonterio A; Zanda M
Bioorg Med Chem Lett; 2009 Aug; 19(16):4715-9. PubMed ID: 19596577
[TBL] [Abstract][Full Text] [Related]
19. Enkephalin-degrading dipeptidylaminopeptidase: characterization of the active site and selective inhibition.
Chérot P; Devin J; Fournié-Zaluski MC; Roques BP
Mol Pharmacol; 1986 Oct; 30(4):338-44. PubMed ID: 3531805
[TBL] [Abstract][Full Text] [Related]
20. Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension.
Fournié-Zaluski MC; Gonzalez W; Turcaud S; Pham I; Roques BP; Michel JB
Proc Natl Acad Sci U S A; 1994 Apr; 91(9):4072-6. PubMed ID: 8171037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
